Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (1158)	1/27/1998 12:21:00 AM
From: Alys Hall	Read Replies (2) \| Respond to of 3702

Davis...my friend...If NJ is the seller and someone has been buying and it isn't us...where is Tustin? You've been speaking up on the side of management of late, don't tell me they weren't prepared for this onslught? After all, they engineered the deal and then in order to facilitate the debacle, they manage to get themselves sold out on margin calls...and that's the caliber of management. Somewhere back in the posts, if someone wants to dig them out...Shero warned management that this could/would happen. Somewhere back there Celeryroot and Brenda warned that this would happen. Not so, said many of the folks, and they were castigated for their audacity and questioned about their veracity. Now here we are and I ask you again...when you talk with Bix and Lon and Rudy...Where in the hell are they...and what do they have in store for us to fix this minor problem? More margin calls or more furniture....or possibly a licensing agreement, phase III testing...something! Or will we now be left with a debate, useless though it may be, on whether or not the stock gets delisted. What a departure from the discussion of when we get NMS listing. We can't get rid of management, they have effectively preserved the status quo by enabling this scenario to take place and they won't or can't do anything to move the Company forward..so what's left?

To: EZLibra who wrote (1158)	1/27/1998 4:10:00 AM
From: Maurice Winn	Read Replies (1) \| Respond to of 3702

Davis, if you are on the committee winding it up, there was a little news item on Coulter, which as you know has an Iodine 131 labelled monoclonal antibody nearly ready for Non-Hodgkins Lymphoma treatment called Bexxar. The news item said: "Bexxar's unique efficacy/safety profile should result in worldwide sales of $400 million at peak," he said [analyst Peter Ginsberg]. I wonder whether he allowed any sales of Oncolym? Or Rituxan and other treatments coming up. Maurice